Journal
JOURNAL OF CLINICAL NEUROSCIENCE
Volume 21, Issue 11, Pages 1847-1856Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.jocn.2014.01.018
Keywords
Evidence-based medicine; Guideline; Multiple sclerosis; Review; Treatment
Categories
Funding
- Novartis
- BioCSL
- Genzyme
- Biogen Idec
- Abbott
- Viiv Healthcare
- El Lilly
- GlaxoSmithKline
- Merck Serono
- Bayer-Scherring
- Biogen-Idec
- Merck-Serono
- Sanofi-Genzyme
- CSL Biopharma
- Bayer Schering Pharma
- Teva
- Aspreva
- Baxter
- Bayer Schering
Ask authors/readers for more resources
In Part 2 of this three part review of multiple sclerosis (MS) treatment with a particular focus on the Australian and New Zealand perspective, we review the newer therapies that have recently become available and emerging therapies that have now completed phase III clinical trial programs. We go on to compare the relative efficacies of these newer and emerging therapies alongside the existing therapies. The effectiveness of beta-interferon in the treatment of different stages and the different disease courses of MS is critically reviewed with the conclusion that the absolute level of response in term of annualised relapse rates (where relapses occur) and MRI activity are similar, but are disappointing in terms of sustained disability progression for progressive forms of the disease. Finally we review the controversial area of combination therapy for MS. Whilst it remains the case that we have no cure or means of preventing MS, we do have a range of effective therapies that when used appropriately and early in the disease course can have a significant impact on short term and longer term outcomes. Crown Copyright (C) 2014 Published by Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available